Treatment of multiple sclerosis with peptide-coupled red blood cells induces antigen-specific T regulatory cells.
Andreas Lutterotti, Thomas Ludersdorfer, María José Docampo et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase Ib clinical trial evaluated the safety and efficacy of peptide-coupled red blood cells (pcRBCs) in patients with multiple sclerosis (MS). The treatment was well tolerated, with stable clinical and imaging outcomes, and a reduction in neurofilament light chain, indicating decreased brain inflammation. Notably, there was an expansion of antigen-specific CD4+ memory T regulatory cells three months post-treatment.
Key findings
- pcRBCs were safe and well tolerated in the trial.
- Neurofilament light chain levels decreased, indicating reduced brain inflammation.
- Expansion of antigen-specific CD4+ memory T regulatory cells was observed three months after treatment.
- A reduction in autoreactive CD4+ T cell responses was noted post-treatment.
Why it matters
The study highlights a novel approach to inducing antigen-specific immune tolerance in multiple sclerosis, which could lead to improved management of this autoimmune condition. Understanding the mechanisms of tolerance may inform future therapies.